Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Amylin's $1 billion heavyweight deal

Nature Biotechnology volume 28, page 109 (2010)Cite this article

Subjects

Access through your institution
Buy or subscribe

The agreement comes amid a surge of deals in metabolic disease, particularly for diabetes treatments that have potential weight loss benefits for the obese. For example, on December 23, Paris-based Sanofi-Aventis paid €100 ($143) million for a 19.9% stake in Zealand Pharma. This Copenhagen-based biotech is developing a peptide analog of Amylin's Byetta (glucagon-like peptide 1 (GLP-1)/exendin 4) for type 2 diabetes, which has also shown efficacy in promoting weight loss. In what has become a crowded market, products will likely gain a competitive edge if they can fight both metabolic disease and obesity, the latter with a potential market of 300 million people worldwide.

The path to approval for Amylin and its competitors won't be easy.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Hayley Birch
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Birch, H. Amylin's $1 billion heavyweight deal. Nat Biotechnol 28, 109 (2010). https://doi.org/10.1038/nbt0210-109

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt0210-109

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research